Cancer immunotherapy: The dark side of PD-1 receptor inhibition.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 29143822.
- Also identified by DOI 10.1038/nature24759 and PMC identifier PMC5019749.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Inhibiting the protein PD-1 can activate T cells that trigger immune responses against tumour cells. But it emerges that, in mice, this immunotherapy exacerbates a cancer that involves the T cells themselves.